| 前收盘价格 | 8.31 |
| 收盘价格 | 8.33 |
| 成交量 | 952,143 |
| 平均成交量 (3个月) | 8,749,742 |
| 市值 | 2,835,198,464 |
| 价格/销量 (P/S) | 106.33 |
| 股市价格/股市净资产 (P/B) | 8.81 |
| 52周波幅 |
| 营业利益率 (TTM) | -1,913.23% |
| 稀释每股收益 (EPS TTM) | -2.20 |
| 总债务/股东权益 (D/E MRQ) | 2.72% |
| 流动比率 (MRQ) | 9.01 |
| 营业现金流 (OCF TTM) | -157.34 M |
| 杠杆自由现金流 (LFCF TTM) | -64.76 M |
| 资产报酬率 (ROA TTM) | -23.33% |
| 股东权益报酬率 (ROE TTM) | -119.66% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Nuvation Bio Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -4.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.20 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 19.14% |
| 机构持股比例 | 62.26% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 25,954,439 |
| Laurion Capital Management Lp | 30 Sep 2025 | 9,705,532 |
| Omega Fund Management, Llc | 30 Sep 2025 | 8,831,089 |
| Tang Capital Management Llc | 30 Sep 2025 | 4,200,000 |
| Abrams Capital Management, L.P. | 30 Sep 2025 | 3,811,513 |
| Redmile Group, Llc | 30 Sep 2025 | 3,031,009 |
| Aisling Capital Management Lp | 30 Sep 2025 | 2,960,659 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 12.00 (B. Riley Securities, 45.11%) | 购买 |
| 中 | 10.00 (20.92%) | |
| 低 | 6.00 (Wedbush, -27.45%) | 购买 |
| 平均值 | 9.57 (15.72%) | |
| 总计 | 7 购买 | |
| 平均价格@调整类型 | 5.95 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Dec 2025 | 10.00 (20.92%) | 购买 | 7.88 |
| 19 Sep 2025 | 10.00 (20.92%) | 购买 | 3.22 | |
| Truist Securities | 24 Nov 2025 | 11.00 (33.01%) | 购买 | 7.41 |
| Citizens | 20 Nov 2025 | 10.00 (20.92%) | 购买 | 7.01 |
| 04 Nov 2025 | 8.00 (-3.26%) | 购买 | 4.83 | |
| B. Riley Securities | 19 Nov 2025 | 12.00 (45.10%) | 购买 | 7.15 |
| RBC Capital | 04 Nov 2025 | 8.00 (-3.26%) | 购买 | 4.83 |
| Wedbush | 13 Oct 2025 | 6.00 (-27.45%) | 购买 | 3.68 |
| 08 Sep 2025 | 6.00 (-27.45%) | 购买 | 3.49 | |
| Jefferies | 30 Sep 2025 | 10.00 (20.92%) | 购买 | 3.70 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| LIU DONGFANG | - | 7.95 | -20,000 | -158,900 |
| 累积净数量 | -20,000 | |||
| 累积净值 ($) | -158,900 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 7.95 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| LIU DONGFANG | 职员 | 26 Nov 2025 | 卖 (-) | 10,000 | 8.01 | 80,100 |
| LIU DONGFANG | 职员 | 26 Nov 2025 | 执行期权 | 10,000 | - | - |
| LIU DONGFANG | 职员 | 25 Nov 2025 | 卖 (-) | 10,000 | 7.88 | 78,800 |
| LIU DONGFANG | 职员 | 25 Nov 2025 | 执行期权 | 10,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合